114 related articles for article (PubMed ID: 8148665)
21. Responsiveness to 1,25-dihydroxyvitamin D3 is reduced in lymphocytes from osteoporotic women.
Koren R; Ravid A; Liberman UA; Narinsky R; Maron L; Weisman M; Samuel R
J Bone Miner Res; 1992 Sep; 7(9):1057-61. PubMed ID: 1414498
[TBL] [Abstract][Full Text] [Related]
22. Ovariectomized murine model of postmenopausal calcium malabsorption.
Kalu DN; Chen C
J Bone Miner Res; 1999 Apr; 14(4):593-601. PubMed ID: 10234581
[TBL] [Abstract][Full Text] [Related]
23. Calcitriol load test in postmenopausal osteoporosis: a pilot study.
Stefikova K; Spustova V; Krivosikova Z; Dzurik R
Bratisl Lek Listy; 2004; 105(5-6):211-4. PubMed ID: 15535112
[TBL] [Abstract][Full Text] [Related]
24. Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis.
Dechant KL; Goa KL
Drugs Aging; 1994 Oct; 5(4):300-17. PubMed ID: 7827399
[TBL] [Abstract][Full Text] [Related]
25. Calcium and calcitriol therapy in osteoporotic postmenopausal women with impaired calcium absorption.
Need AG; Nordin C; Horowitz M; Morris HA
Metabolism; 1990 Apr; 39(4 Suppl 1):53-4. PubMed ID: 2325573
[TBL] [Abstract][Full Text] [Related]
26. Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D
Liao EY; Zhang ZL; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; Peng YD; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L
BMC Musculoskelet Disord; 2018 Jul; 19(1):210. PubMed ID: 29970059
[TBL] [Abstract][Full Text] [Related]
27. Evidence for vitamin D-independent active calcium absorption in newborn piglets.
Schröder B; Kaune R; Schlumbohm C; Breves G; Harmeyer J
Calcif Tissue Int; 1993 Apr; 52(4):305-9. PubMed ID: 8385545
[TBL] [Abstract][Full Text] [Related]
28. Long-term treatment with calcitriol in postmenopausal osteoporosis.
Caniggia A; Nuti R; Lore F; Martini G; Turchetti V; Righi G
Metabolism; 1990 Apr; 39(4 Suppl 1):43-9. PubMed ID: 2325571
[TBL] [Abstract][Full Text] [Related]
29. Effect of long term treatment with calcitriol on calcium absorption and mineral metabolism in postmenopausal osteoporosis.
Riggs BL; Nelson KI
J Clin Endocrinol Metab; 1985 Sep; 61(3):457-61. PubMed ID: 3926808
[TBL] [Abstract][Full Text] [Related]
30. Pernicious anaemia as a risk factor for osteoporosis.
Eastell R; Vieira NE; Yergey AL; Wahner HW; Silverstein MN; Kumar R; Riggs BL
Clin Sci (Lond); 1992 Jun; 82(6):681-5. PubMed ID: 1320549
[TBL] [Abstract][Full Text] [Related]
31. Combined treatment with calcitonin and 1,25-dihydroxyvitamin D3 for osteoporosis in women.
Eriksson SA; Lindgren JU
Calcif Tissue Int; 1993 Jul; 53(1):26-8. PubMed ID: 8348381
[TBL] [Abstract][Full Text] [Related]
32. Metabolic effects of thiazide and 1,25-(OH)2 vitamin D in postmenopausal osteoporosis.
Sakhaee K; Zisman A; Poindexter JR; Zerwekh JE; Pak CY
Osteoporos Int; 1993 Jul; 3(4):209-14. PubMed ID: 8338977
[TBL] [Abstract][Full Text] [Related]
33. Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
Malavolta N; Zanardi M; Veronesi M; Ripamonti C; Gnudi S
Int J Tissue React; 1999; 21(2):51-9. PubMed ID: 10568224
[TBL] [Abstract][Full Text] [Related]
34. Skeletal responsiveness to endogenous parathyroid hormone in postmenopausal osteoporosis.
Ebeling PR; Jones JD; Burritt MF; Duerson CR; Lane AW; Hassager C; Kumar R; Riggs BL
J Clin Endocrinol Metab; 1992 Oct; 75(4):1033-8. PubMed ID: 1400868
[TBL] [Abstract][Full Text] [Related]
35. Association between intestinal vitamin D receptor, calcium absorption, and serum 1,25 dihydroxyvitamin D in normal young and elderly women.
Kinyamu HK; Gallagher JC; Prahl JM; DeLuca HF; Petranick KM; Lanspa SJ
J Bone Miner Res; 1997 Jun; 12(6):922-8. PubMed ID: 9169351
[TBL] [Abstract][Full Text] [Related]
36. Relations between calcium intake, calcitriol, polymorphisms of the vitamin D receptor gene, and calcium absorption in premenopausal women.
Wishart JM; Horowitz M; Need AG; Scopacasa F; Morris HA; Clifton PM; Nordin BE
Am J Clin Nutr; 1997 Mar; 65(3):798-802. PubMed ID: 9062532
[TBL] [Abstract][Full Text] [Related]
37. Responsiveness of the intestinal 1,25-dihydroxyvitamin D3 receptor to magnesium depletion in the rat.
Lemay J; Gascon-Barré M
Endocrinology; 1992 May; 130(5):2767-77. PubMed ID: 1315257
[TBL] [Abstract][Full Text] [Related]
38. Evidence of an age-related decrease in intestinal responsiveness to vitamin D: relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women.
Ebeling PR; Sandgren ME; DiMagno EP; Lane AW; DeLuca HF; Riggs BL
J Clin Endocrinol Metab; 1992 Jul; 75(1):176-82. PubMed ID: 1320048
[TBL] [Abstract][Full Text] [Related]
39. Ability of 25-hydroxyvitamin D3 therapy to augment serum 1,25- and 24,25-dihydroxyvitamin D in postmenopausal osteoporosis.
Lawoyin S; Zerwekh JE; Glass K; Pak CY
J Clin Endocrinol Metab; 1980 Mar; 50(3):593-6. PubMed ID: 6965678
[TBL] [Abstract][Full Text] [Related]
40. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Stuss M; Rieske P; Cegłowska A; Stêpień-Kłos W; Liberski PP; Brzeziańska E; Sewerynek E
J Clin Endocrinol Metab; 2013 May; 98(5):E1007-11. PubMed ID: 23543663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
